Breaking News: Actinium Pharmaceuticals Investors Allegedly Affected by Securities Fraud
New York, April 11, 2025 – Levi & Korsinsky, LLP announces that a class action securities lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors in Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE: ATNM). The lawsuit seeks to recover losses on behalf of Actinium investors who were adversely affected by alleged securities fraud between October 31, 2022, and August 2, 2024.
Class Definition
The class action consists of all persons or entities who purchased or otherwise acquired securities of Actinium between October 31, 2022, and August 2, 2024, inclusive (the “Class Period”).
Allegations
According to the complaint, Actinium and certain of its top executives allegedly made false and misleading statements to the market. Specifically, the Company is accused of misrepresenting the commercial prospects of its lead therapeutic candidate, I-131 Apatorsen, and its development timeline.
Timeline of Events
-
October 31, 2022: Actinium announces positive data from a Phase 1b study of I-131 Apatorsen in combination with low-dose cytarabine (LDAC) in patients with relapsed or refractory acute myeloid leukemia (AML).
-
December 16, 2022: Actinium announces that it has initiated a pivotal Phase 3 study of I-131 Apatorsen in combination with LDAC in patients with relapsed or refractory AML.
-
June 21, 2023: Actinium announces that the Phase 3 study has met its primary endpoint, demonstrating a statistically significant improvement in overall survival compared to LDAC alone.
-
August 2, 2024: Actinium announces that the FDA has placed a hold on the Phase 3 study due to safety concerns, casting doubt on the commercial prospects of I-131 Apatorsen.
Implications for Individual Investors
If you invested in Actinium during the Class Period, you may be entitled to recover your losses, including damages. To learn more about the class action, contact Levi & Korsinsky, LLP.
Global Impact
The securities fraud allegations against Actinium could have significant ramifications for the biotech industry as a whole. Investors may become more cautious when considering investments in other pharmaceutical companies, particularly those with promising but unproven therapeutic candidates. Regulatory agencies may also be under increased scrutiny to ensure the accuracy and transparency of clinical trial data.
Conclusion
The recent securities fraud allegations against Actinium Pharmaceuticals could have far-reaching implications for both individual investors and the biotech industry. Levi & Korsinsky, LLP is dedicated to helping investors recover their losses. For more information, contact the firm today.
Disclaimer: This communication is not an offer to sell or the solicitation of an offer to buy any security. The information contained herein is for informational purposes only and does not constitute investment advice. Your receipt of this material does not create a client-attorney relationship between you and Levi & Korsinsky, LLP. The facts and circumstances of your investment may differ from those in any of the materials represented herein. Please contact Levi & Korsinsky, LLP to determine which securities may be affected.
